Title: 
Official Title: To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Number of Sections: 1
Source: versions - Introduced in House
Media Type: text/xml

================================================================================

Section 1:
1.Nullification of modifications to REMS for mifepristone(a)NullificationThe modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone are hereby nullified.(b)No substantially similar provisionsThe Secretary of Health and Human Services (or any head of any office, department, or agency of the Department of Health and Human Services) shall not establish, implement, or enforce any provision of a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a).


================================================================================

Raw Text:
119 HR 679 IH: To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
U.S. House of Representatives
2025-01-23
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.



I119th CONGRESS1st SessionH. R. 679IN THE HOUSE OF REPRESENTATIVESJanuary 23, 2025Mrs. Harshbarger (for herself, Mr. Hern of Oklahoma, Mr. Bost, Mrs. Miller of Illinois, Mr. Weber of Texas, Mr. Babin, Mr. Moolenaar, Mr. Webster of Florida, Mr. Baird, Mr. Higgins of Louisiana, Mr. Feenstra, Mr. Yakym, Mr. Biggs of Arizona, Mr. Palmer, and Mr. Guest) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.1.Nullification of modifications to REMS for mifepristone(a)NullificationThe modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone are hereby nullified.(b)No substantially similar provisionsThe Secretary of Health and Human Services (or any head of any office, department, or agency of the Department of Health and Human Services) shall not establish, implement, or enforce any provision of a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a).